Brief: Nanobiotix Transfers Sponsorship Of Nanoray-312 To J&J

Nanobiotix SA

24/10/2025 07:03

Oct 24 (Reuters) - Nanobiotix SA NANOB.PA:

NANOBIOTIX ANNOUNCES UPDATES TO JNJ-1900 (NBTXR3) CLINICAL PROGRAM FOLLOWING TRANSFER OF ONGOING PHASE 3 HEAD AND NECK CANCER TRIAL SPONSORSHIP AND OPERATIONAL CONTROL

NANORAY-312 INTERIM DATA EXPECTED IN 1H2027

TRANSFERS NANORAY-312 SPONSORSHIP AND CONTROL TO J&J

FUTURE GUIDANCE RELATED TO NANORAY-312 AND OTHER JNJ-1900 (NBTXR3)-RELATED J&J-SPONSORED STUDIES WILL BE COMMUNICATED BY J&J

Source text: ID:nGNX7P4DxF

Further company coverage: NANOB.PAJNJ.N

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))